news-date">15.11.2021
Women who receive an mRNA COVID-19 vaccine during pregnancy pass high levels of antibodies on to their babies. This is the result of an American study published in the American Journal of Obstetrics & Gynecology.
The effectiveness of Pfizer-BioNTech and Moderna’s mRNA vaccines, according to the researchers, lies in their ability to trigger the production of the right antibodies, proteins that can protect people from infection. Whether this protection could pass to their babies before the birth of mothers has not yet been fully clarified.
In the current American study, 36 newborns whose mothers received either the Pfizer BioNTech or Moderna COVID-19 vaccine while pregnant were at birth. Antibodies on.
Antibodies can either be produced as part of the natural response to infection or triggered by vaccines. The research team was able to distinguish the antibodies in the newborn’s blood that were made in response to a natural infection from those made in response to the vaccines. This is important as natural antibody responses to the SARS-CoV-2Virus does not provide adequate protection for many people.
Led by researchers from NYU Grossman School of Medicine, the study authors observed the highest levels of antibodies in the umbilical cord blood of mothers who were fully vaccinated during the latter half of their pregnancies. This finding provides evidence of a transferred immunity to newborns, which correlates with protection against infection for infants in the first months of life.
“Studies continue to underline the importance of vaccines during pregnancy and their ability to protect two lives at the same time by preventing serious illnesses in both mothers and babies,” said Prof. Dr. Ashley S. Roman, MD, one of the study authors. “If babies are born with antibodies, they would be protected for the first few months of their life when they are most at risk.”
Prof. Dr. With their study, Roman and colleagues confirm that the mRNA vaccines are safe during pregnancy. The study found no increased risks during pregnancy, birth complications, or identifiable risks to the fetus in the group that received the vaccine.
In the current study, the sample size is small, but ” [es ist] It is encouraging that the antibody levels in newborns are high when women are vaccinated, ”explained Prof. Dr. Jennifer L. Lighter, lead author on the study.
Previous research only analyzes antibodies against the spike protein (anti-S-IgG), which can be present after a natural infection or vaccination, and no antibodies against the nucleocapsid protein (anti-N-IgG), which only after a natural one Infection is formed. Of the 36 samples collected, all had high levels of anti-S IgG. Of these samples, 31 tested for anti-N-IgG and were negative.
“A high transplacental antibody transfer is not surprising. It is consistent with what we see with other vaccinations. Our results add to a growing list of important reasons for a COVID-19 vaccination during pregnancy, as newborns also receive crucial additional protection, “added Prof. Dr. Lighter.
More research is needed to determine how effective the infant’s antibodies are, how long protection lasts, and whether vaccination in the second half of pregnancy may result in higher antibody transfer than vaccination earlier in pregnancy. Future studies should also focus on antibody delivery to newborns in more female participants and duration of protection in infants.
Those: ScienceDaily, NYU Langone Health / NYU Grossman School of Medicine, American Journal of Obstetrics & Gynecology
–
